Topics Covered
- Levetiracetam
- Antiepileptic Drug Discovery
- Levetiracetam in electroshock and PTZ seizures
- Protection against seizures in rat model
- Levetiracetam activity in GAERS model
- Impact on cognitive function
- Hyper-synchronization / excitability inhibition in vitro
- Effect on development of amygdala kindling
- Effect on seizures in genetic models of epilepsy
- Inactivation of sodium channels
- Reduction of current through T-type Ca channels
- Levetiracetam mechanism of action
- SV2 proteins: candidates for the LEV binding site
- SV2A cloning and binding studies
- Levetiracetam studies in SV2A (+/-) mice
- Profile of new class of antiepileptic drugs
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Klitgaard, H. (2013, March 28). Discovery of Levetiracetam (Keppra(R)): The first SV2A ligand for the treatment of epilepsy [Video file]. In
The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved June 25, 2022, from
https://hstalks.com/bs/2524/.
Publication History
-
Published on March 28, 2013
Financial Disclosures
- Dr. Henrik Klitgaard has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.